The Xalkori Clinical Trial Package
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Because Pfizer had already started its Phase III trials before filing for accelerated approval, FDA was able to piggy-back most of its post-marketing requirements onto ongoing studies.